{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:14:05Z","timestamp":1783509245884,"version":"3.55.0"},"reference-count":94,"publisher":"MDPI AG","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:p>Cancer is one of the leading causes of mortality and morbidity worldwide. Recent improved therapies have resulted in more patients surviving cancer and living longer. Despite these advances, the majority of patients will develop adverse events from anticancer therapies. Foot alterations, including nail toxicities, hand-foot syndrome, edema, xerosis, hyperkeratosis, and neuropathy, are frequent among cancer patients. These untoward conditions may negatively impact quality of life, and in some cases may result in the interruption or discontinuation of cancer treatments. Appropriate prevention, diagnosis, and management of podiatric adverse events are essential to maintain foot function and health-related quality of life, both of which are critical for the care of cancer patients and survivors. This article shows results related to complaint and impact on quality of life of the Oncology Foot Care program and reviews publications specific to podiatric adverse events related to cancer treatments.<\/jats:p>","DOI":"10.7547\/17-010","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T16:24:31Z","timestamp":1549902271000},"page":"508-516","source":"Crossref","is-referenced-by-count":6,"title":["Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors"],"prefix":"10.3390","volume":"108","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kopsky","sequence":"additional","affiliation":[{"name":"Institute for Neuropathic Pain, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Lilker","sequence":"additional","affiliation":[{"name":"Coney Island Hospital, Brooklyn, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Damstra","sequence":"additional","affiliation":[{"name":"Reade Rehabilitation Centre, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mecheline H.M.","family":"van der Linden","sequence":"additional","affiliation":[{"name":"VUMC University Medical Center, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azael","family":"Freites-Martinez","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mischa P.M.","family":"Nagel","sequence":"additional","affiliation":[{"name":"Medische Voet and Supplement, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"ref581","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.14694\/EdBook_AM.2015.35.e553","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?","author":"Cavaletti","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","article-title":"Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref411","first-page":"29","article-title":"Chronic paronychia. Short review of 590 cases","volume":"38","author":"Frain-Bell","year":"1957","journal-title":"Trans St John's Hosp Dermatol Soc"},{"key":"ref151","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1346-8138.13205","article-title":"Effective treatments for paronychia caused by oncology pharmacotherapy","volume":"43","author":"Goto","year":"2016","journal-title":"J Dermatol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot' syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann Oncol"},{"key":"ref891","first-page":"29","article-title":"Chronic paronychia. Short review of 590 cases","volume":"38","author":"Frain-Bell","year":"1957","journal-title":"Trans St John's Hosp Dermatol Soc"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-16366-6_6","article-title":"Symptoms: chemotherapy-induced peripheral neuropathy","volume":"862","author":"Schneider","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4097\/kjae.2014.67.1.4","article-title":"Chemotherapy induced peripheral neuropathic pain","volume":"67","author":"Park","year":"2014","journal-title":"Korean J Anesthesiol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcpt.12262","article-title":"Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires","volume":"115","author":"Zedan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"71133","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10637-013-9927-x","article-title":"The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis","volume":"31","author":"Fischer","year":"2013","journal-title":"Invest New Drugs"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10637-013-9927-x","article-title":"The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis","volume":"31","author":"Fischer","year":"2013","journal-title":"Invest New Drugs"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"ref201","article-title":"Effects of chemotherapy-induced-peripheral-neuropathy on spatiotemporal gait parameters and fall risk in cancer patients after the completion of chemotherapy drug treatment (dissertation)","author":"Marshall","year":"2016","journal-title":"Seton Hall University Dissertations and Theses"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/CCID.S90542","article-title":"Chemotherapy-associated paronychia treated with a dilute povidone-iodine\/dimethylsulfoxide preparation","volume":"8","author":"Capriotti","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref61","article-title":"Foot care in oncology: the cancer patient from ankle to toe","author":"Nagel","journal-title":"The ASCO Post"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/00325481.1970.11697570","article-title":"How we treat paronychia","volume":"48","author":"Fliegelman","year":"1970","journal-title":"Postgrad Med"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-16366-6_6","article-title":"Symptoms: chemotherapy-induced peripheral neuropathy","volume":"862","author":"Schneider","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.fas.2015.09.003","article-title":"Toenail paronychia","volume":"22","author":"Lomax","year":"2016","journal-title":"Foot Ankle Surg"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4097\/kjae.2014.67.1.4","article-title":"Chemotherapy induced peripheral neuropathic pain","volume":"67","author":"Park","year":"2014","journal-title":"Korean J Anesthesiol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40279-014-0207-5","article-title":"Exercise intervention studies in patients with peripheral neuropathy: a systematic review","volume":"44","author":"Streckmann","year":"2014","journal-title":"Sports Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"508","DOI":"10.7547\/1030508","article-title":"Does footwear affect balance?: the views and experiences of people with diabetes and neuropathy who have fallen","volume":"103","author":"Paton","year":"2013","journal-title":"JAPMA"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcpt.12262","article-title":"Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires","volume":"115","author":"Zedan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","article-title":"Development and validation of the Neuropathic Pain Symptom Inventory","volume":"108","author":"Bouhassira","year":"2004","journal-title":"Pain"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot' syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11916-014-0459-7","article-title":"Cancer treatment-related neuropathic pain syndromes\u2014epidemiology and treatment: an update","volume":"18","author":"Smith","year":"2014","journal-title":"Curr Pain Headache Rep"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.fas.2015.09.003","article-title":"Toenail paronychia","volume":"22","author":"Lomax","year":"2016","journal-title":"Foot Ankle Surg"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"71133","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","author":"Dranitsaris","year":"2012","journal-title":"Ann Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.14694\/EdBook_AM.2015.35.e553","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?","author":"Cavaletti","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref831","first-page":"AB65","article-title":"Topical nonocclusive polymers in hand-foot skin reaction","volume":"72","author":"Ionescu","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.gerinurse.2015.07.003","article-title":"Optimal choice of footwear in the elderly population","volume":"36","author":"Lopez Lopez","year":"2015","journal-title":"Geriatr Nurs"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref681","article-title":"Effects of chemotherapy-induced-peripheral-neuropathy on spatiotemporal gait parameters and fall risk in cancer patients after the completion of chemotherapy drug treatment (dissertation)","author":"Marshall","year":"2016","journal-title":"Seton Hall University Dissertations and Theses"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/00325481.1970.11697570","article-title":"How we treat paronychia","volume":"48","author":"Fliegelman","year":"1970","journal-title":"Postgrad Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","article-title":"Development and validation of the Neuropathic Pain Symptom Inventory","volume":"108","author":"Bouhassira","year":"2004","journal-title":"Pain"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.gerinurse.2015.07.003","article-title":"Optimal choice of footwear in the elderly population","volume":"36","author":"Lopez Lopez","year":"2015","journal-title":"Geriatr Nurs"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"key":"ref631","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"508","DOI":"10.7547\/1030508","article-title":"Does footwear affect balance?: the views and experiences of people with diabetes and neuropathy who have fallen","volume":"103","author":"Paton","year":"2013","journal-title":"JAPMA"},{"key":"ref351","first-page":"AB65","article-title":"Topical nonocclusive polymers in hand-foot skin reaction","volume":"72","author":"Ionescu","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1346-8138.13205","article-title":"Effective treatments for paronychia caused by oncology pharmacotherapy","volume":"43","author":"Goto","year":"2016","journal-title":"J Dermatol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref541","article-title":"Foot care in oncology: the cancer patient from ankle to toe","author":"Nagel","journal-title":"The ASCO Post"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/JTO.0b013e318207f788","article-title":"A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed","volume":"6","author":"D'Angelo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/JTO.0b013e318207f788","article-title":"A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed","volume":"6","author":"D'Angelo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/CCID.S90542","article-title":"Chemotherapy-associated paronychia treated with a dilute povidone-iodine\/dimethylsulfoxide preparation","volume":"8","author":"Capriotti","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40279-014-0207-5","article-title":"Exercise intervention studies in patients with peripheral neuropathy: a systematic review","volume":"44","author":"Streckmann","year":"2014","journal-title":"Sports Med"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","article-title":"Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","author":"Dranitsaris","year":"2012","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11916-014-0459-7","article-title":"Cancer treatment-related neuropathic pain syndromes\u2014epidemiology and treatment: an update","volume":"18","author":"Smith","year":"2014","journal-title":"Curr Pain Headache Rep"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/108\/6\/508\/2003253\/17-010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/108\/6\/508\/2003253\/17-010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:17:32Z","timestamp":1783505852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/108\/6\/508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.7547\/17-010","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}